Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M. Frohman EM, et al. Among authors: racke mk. Arch Neurol. 2006 Apr;63(4):614-9. doi: 10.1001/archneur.63.4.614. Arch Neurol. 2006. PMID: 16606781 No abstract available.
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stüve O. del Pilar Martin M, et al. Among authors: racke mk. Arch Neurol. 2008 Dec;65(12):1596-603. doi: 10.1001/archneur.65.12.noc80051. Epub 2008 Oct 13. Arch Neurol. 2008. PMID: 18852339 Clinical Trial.
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radü EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK. Stüve O, et al. Among authors: racke mk. Neurology. 2009 Feb 3;72(5):396-401. doi: 10.1212/01.wnl.0000327341.89587.76. Epub 2008 Nov 5. Neurology. 2009. PMID: 18987352 Free PMC article. Clinical Trial.
Monoclonal antibody therapies and neurologic disorders.
Novak JC, Lovett-Racke AE, Racke MK. Novak JC, et al. Among authors: racke mk. Arch Neurol. 2008 Sep;65(9):1162-5. doi: 10.1001/archneur.65.9.1162. Arch Neurol. 2008. PMID: 18779418 Review.
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD. Nash RA, et al. Among authors: racke mk. Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1. Neurology. 2017. PMID: 28148635 Free PMC article. Clinical Trial.
197 results